{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:10:08Z","timestamp":1782990608159,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>There is growing evidence that Parkinson\u2019s disease and diabetes are partially related diseases; however, the association between the two, and the impact of specific treatments, are still unclear. We evaluated the effect of T2D and antidiabetic treatment on age at PD onset and on all-cause mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Research design and methods<\/jats:title>\n                <jats:p>The standardized rate of T2D was calculated for PD patients using the direct method and compared with subjects with essential tremor (ET) and the general Italian population. Age at onset and survival were also compared between patients without T2D (PD-noT2D), patients who developed T2D before PD onset (PD-preT2D) and patients who developed T2D after PD onset (PD-postT2D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We designed a retrospective and prospective study. The T2D standardized ratio of PD (<jats:italic>N<\/jats:italic>\u2009=\u20098380) and ET (<jats:italic>N<\/jats:italic>\u2009=\u20091032) patients was 3.8% and 6.1%, respectively, while in the Italian general population, the overall prevalence was 5.3%. In PD-preT2D patients, on antidiabetic treatment, the onset of PD was associated with a\u2009+\u20096.2\u00a0year delay (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) while no difference was observed in PD-postT2D. Occurrence of T2D before PD onset negatively affected prognosis (adjusted hazard ratio\u2009=\u20091.64 [95% CI 1.33\u20132.02]; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while no effect on survival was found in PD-postT2D subjects (hazard ratio\u2009=\u20090.86, [95% CI 0.53\u20131.39]; <jats:italic>p<\/jats:italic>\u2009=\u20090.54).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>T2D, treated with any antidiabetic therapy before PD, is associated with a delay in its onset. Duration of diabetes increases mortality in PD-preT2D, but not in PD-postT2D. These findings prompt further studies on antidiabetic drugs as a potential disease-modifying therapy for PD.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11496-y","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:28:29Z","timestamp":1669548509000},"page":"1564-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Onset and mortality of Parkinson\u2019s disease in relation to type II diabetes"],"prefix":"10.1007","volume":"270","author":[{"given":"Gianni","family":"Pezzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-1951","authenticated-orcid":false,"given":"Emanuele","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Amami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Barichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Sacilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zecchinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Zini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Bolliri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calandrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Reali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Caronni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Cassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Canesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"del Sorbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Soliveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis U.","family":"Isaias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"issue":"8","key":"11496_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm 124(8):901\u2013905","journal-title":"J Neural Transm"},{"issue":"s1","key":"11496_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloemd BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinson\u2019s Dis 8(s1):S3\u2013S8","journal-title":"J Parkinson\u2019s Dis"},{"issue":"10","key":"11496_CR3","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson\u2019s disease: Insights into motor complications from sub-Saharan Africa. Brain 137(10):2731\u20132742","journal-title":"Brain"},{"issue":"5","key":"11496_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ (2018) Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 33(5):660\u2013677","journal-title":"Mov Disord"},{"issue":"2","key":"11496_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Limousin P, Lees A, Foltynie T (2013) Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain 136(2):374\u2013384","journal-title":"Brain"},{"issue":"3","key":"11496_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/brain\/awu369","volume":"138","author":"T Gjerl\u00f8ff","year":"2015","unstructured":"Gjerl\u00f8ff T, Fedorova T, Knudsen K et al (2015) Imaging acetylcholinesterase density in peripheral organs in Parkinson\u2019s disease with 11 C-donepezil PET. Brain 138(3):653\u2013663","journal-title":"Brain"},{"key":"11496_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13731","author":"MW Klinge","year":"2020","unstructured":"Klinge MW, Borghammer P, Lund S et al (2020) Enteric cholinergic neuropathy in patients with diabetes: non-invasive assessment with positron emission tomography. Neurogastroenterol Motility. https:\/\/doi.org\/10.1111\/nmo.13731","journal-title":"Neurogastroenterol Motility"},{"issue":"6","key":"11496_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Arizona Parkinson\u2019s Disease Consortium, Beach TG, Adler CH et al (2010) Multi-organ distribution of phosphorylated \u03b1-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119(6):689\u2013702","journal-title":"Acta Neuropathol"},{"issue":"6","key":"11496_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","volume":"135","author":"I Martinez-Valbuena","year":"2018","unstructured":"Martinez-Valbuena I, Amat-Villegas I, Valenti-Azcarate R et al (2018) Interaction of amyloidogenic proteins in pancreatic \u03b2 cells from subjects with synucleinopathies. Acta Neuropathol 135(6):877\u2013886","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"11496_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","volume":"315","author":"D Bosco","year":"2012","unstructured":"Bosco D, Plastino M, Cristiano D et al (2012) Dementia is associated with Insulin Resistance in patients with Parkinson\u2019s Disease. J Neurol Sci 315(1\u20132):39\u201343","journal-title":"J Neurol Sci"},{"key":"11496_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2337\/db12-1045","volume":"62","author":"P Steneberg","year":"2013","unstructured":"Steneberg P, Bernardo L, Edfalk S et al (2013) The Type 2 Diabetes-Associated Gene Ide Is Required for Insulin Secretion and Suppression of a-Synuclein Levels in b-Cells. Diabetes 62:2004\u20132014","journal-title":"Diabetes"},{"issue":"3","key":"11496_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","volume":"10","author":"JLY Cheong","year":"2020","unstructured":"Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ (2020) The association between Type 2 diabetes mellitus and Parkinson\u2019s disease. J Parkinson\u2019s Dis 10(3):775\u2013789","journal-title":"J Parkinson\u2019s Dis"},{"key":"11496_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.irn.2020.02.010","volume-title":"Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases","author":"S Cardoso","year":"2020","unstructured":"Cardoso S, Moreira PI (2020) Chapter two\u2014antidiabetic drugs for Alzheimer\u2019s and Parkinson\u2019s diseases: repurposing insulin, metformin, and thiazolidinediones. In: S\u00f6derbom G, Esterline R, Oscarsson J, Mattson MPBT-IR of N (eds) Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Berlin, pp 37\u201364"},{"issue":"12","key":"11496_CR14","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.2337\/dc11-1584","volume":"34","author":"E Cereda","year":"2011","unstructured":"Cereda E, Barichella M, Pedrolli C et al (2011) Diabetes and risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Diabetes Care 34(12):2614\u20132623","journal-title":"Diabetes Care"},{"issue":"6","key":"11496_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan H, Senkevich K, Patel RK et al (2021) Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression. Mov Disord 36(6):1420\u20131429","journal-title":"Mov Disord"},{"issue":"1","key":"11496_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085781","volume":"9","author":"L Lu","year":"2014","unstructured":"Lu L, Fu D, Li H et al (2014) Diabetes and risk of Parkinson\u2019s disease: an updated meta-analysis of case-control studies. PLoS\u00a0One 9(1):e85781","journal-title":"PLoS\u00a0One"},{"key":"11496_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","volume":"78","author":"E Cereda","year":"2012","unstructured":"Cereda E, Barichella M, Cassani E et al (2012) Clinical features of parkinson disease when onset of diabetes came first: a case-control study. Neurology 78:1507\u20131511","journal-title":"Neurology"},{"issue":"19","key":"11496_CR18","doi-asserted-by":"publisher","first-page":"E1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90(19):E1654\u2013E1662","journal-title":"Neurology"},{"issue":"1","key":"11496_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer B, Zimmermann J, Sixel-D\u00f6ring F et al (2019) Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord 34(1):67\u201377","journal-title":"Mov Disord"},{"issue":"4","key":"11496_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/acn3.51343","volume":"8","author":"R Ou","year":"2021","unstructured":"Ou R, Wei Q, Hou Y et al (2021) Effect of diabetes control status on the progression of Parkinson\u2019s disease: a prospective study. Ann Clin Transl Neurol 8(4):887\u2013897","journal-title":"Ann Clin Transl Neurol"},{"issue":"10103","key":"11496_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Clinical C et al (2018) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675","journal-title":"Lancet"},{"issue":"10","key":"11496_CR22","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain 143(10):3067\u20133076","journal-title":"Brain"},{"key":"11496_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012990.pub2","author":"CA Mulvaney","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J et al (2020) GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012990.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"11496_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awab015","volume":"144","author":"SH Jeong","year":"2021","unstructured":"Jeong SH, Chung SJ, Yoo HS et al (2021) Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease. Brain 144(4):1127\u20131137","journal-title":"Brain"},{"key":"11496_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.713418","volume":"12","author":"G Tavares","year":"2021","unstructured":"Tavares G, Martins FO, Melo BF et al (2021) Peripheral dopamine directly acts on insulin-sensitive tissues to regulate insulin signaling and metabolic function. Front Pharmacol 12:713418","journal-title":"Front Pharmacol"},{"key":"11496_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108173","volume":"175","author":"Y-K Ryu","year":"2020","unstructured":"Ryu Y-K, Go J, Park H-Y et al (2020) Metformin regulates astrocyte reactivity in Parkinson\u2019s disease and normal aging. Neuropharmacology 175:108173","journal-title":"Neuropharmacology"},{"issue":"12","key":"11496_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"issue":"10 Suppl 3","key":"11496_CR28","first-page":"S34","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (2001) What features improve the accuracy of clinical diagnosis in Parkinson\u2019s disease: a clinicopathologic study. 1992. Neurology 57(10 Suppl 3):S34\u2013S38","journal-title":"Neurology"},{"issue":"1","key":"11496_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.27121","volume":"33","author":"KP Bhatia","year":"2018","unstructured":"Bhatia KP, Bain P, Bajaj N et al (2018) Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement Disord 33(1):75\u201387","journal-title":"Movement Disord"},{"issue":"8","key":"11496_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/M15-3016","volume":"164","author":"JJ Chamberlain","year":"2016","unstructured":"Chamberlain JJ, Rhinehart AS, Shaefer CFJ, Neuman A (2016) Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med 164(8):542\u2013552","journal-title":"Ann Intern Med"},{"issue":"5","key":"11496_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","volume":"19","author":"V Kotagal","year":"2013","unstructured":"Kotagal V, Albin RL, M\u00fcller MLTM et al (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19(5):522\u2013526","journal-title":"Parkinsonism Relat Disord"},{"issue":"13","key":"11496_CR32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 361(13):1268\u20131278","journal-title":"N Engl J Med"},{"issue":"4","key":"11496_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000445751","volume":"46","author":"L Hirsch","year":"2016","unstructured":"Hirsch L, Jette N, Frolkis A et al (2016) The incidence of Parkinson\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology 46(4):292\u2013300","journal-title":"Neuroepidemiology"},{"key":"11496_CR34","unstructured":"Istat (2017) Il diabete in Italia anni 2000\u20132016. www.Istat.It"},{"key":"11496_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4951379","volume":"2019","author":"F Camargo Maluf","year":"2019","unstructured":"Camargo Maluf F, Feder D, Alves De Siqueira Carvalho A (2019) Analysis of the relationship between type II diabetes Mellitus and Parkinson\u2019s disease: a systematic review. Parkinson\u2019s Dis 2019:1\u201314","journal-title":"Parkinson\u2019s Dis"},{"issue":"4","key":"11496_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/XCE.0000000000000210","volume":"9","author":"AH Heald","year":"2020","unstructured":"Heald AH, Stedman M, Davies M et al (2020) Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data. Cardiovasc Endocrinol Metab 9(4):183\u2013185","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"June","key":"11496_CR37","first-page":"1","volume":"11","author":"C Sportelli","year":"2020","unstructured":"Sportelli C, Urso D, Jenner P, Chaudhuri KR (2020) Metformin as a potential neuroprotective agent in prodromal Parkinson\u2019s disease\u2014viewpoint. Front Neurol 11(June):1\u201310","journal-title":"Front Neurol"},{"issue":"May","key":"11496_CR38","first-page":"1","volume":"11","author":"E Hustad","year":"2020","unstructured":"Hustad E, Aasly JO (2020) Clinical and imaging markers of prodromal Parkinson\u2019s disease. Front Neurol 11(May):1\u201311","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11496-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:10:05Z","timestamp":1677503405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11496-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["11496"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11496-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"26 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to declare concerning the research related to this manuscript. GP, RC, SC, MZ, MGB, MC, FdS, PS, LZ, and EC: none. PA, MB, GS, VF, CB, DC, VC, ER, SC, EC, CK, and IUI: research grant from the Fondazione Grigioni per il Morbo di Parkinson. AZ: Advisory Board (Expert testimony) for Bial, Zambon, Italfarmaco. MC: Congress support by the International Parkinson and Movement Disorder Society (MDS) and Accademia per lo Studio della Malattia di Parkinson e i Disordini del Movimento (Accademia LIMPE-DISMOV). IUI: research grant by the German Research Foundation (DFG), the Marlene and Paolo Fresco Foundation, and Medtronic Inc. Honoraria from Medtronic Inc and Newronika Spa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest and financial disclosure"}}]}}